WO2000003980A1 - DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF - Google Patents
DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF Download PDFInfo
- Publication number
- WO2000003980A1 WO2000003980A1 PCT/JP1999/003798 JP9903798W WO0003980A1 WO 2000003980 A1 WO2000003980 A1 WO 2000003980A1 JP 9903798 W JP9903798 W JP 9903798W WO 0003980 A1 WO0003980 A1 WO 0003980A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- same
- thia
- prostaglandin
- substituted phenyl
- disease
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010050685 Cytokine storm Diseases 0.000 abstract 1
- 208000013558 Developmental Bone disease Diseases 0.000 abstract 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000011200 Kawasaki disease Diseases 0.000 abstract 1
- 208000004987 Macrophage activation syndrome Diseases 0.000 abstract 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010072610 Skeletal dysplasia Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 231100000354 acute hepatitis Toxicity 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 206010052015 cytokine release syndrome Diseases 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT99929831T ATE291013T1 (de) | 1998-07-15 | 1999-07-14 | Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten |
JP2000560089A JP3174563B2 (ja) | 1998-07-15 | 1999-07-14 | 5−チア−ω−置換フェニル−プロスタグランジンE誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
NZ509293A NZ509293A (en) | 1998-07-15 | 1999-07-14 | 5-Thia-omega-substituted phenyl-prostaglandin E derivatives |
EP99929831A EP1097922B1 (en) | 1998-07-15 | 1999-07-14 | 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient |
DK99929831T DK1097922T3 (da) | 1998-07-15 | 1999-07-14 | 5-Thia-omega-substituerede phenyl-prostaglandin E derivater, fremgangsmåde til fremstilling deraf samt lægemidler indeholdende forbindelsen som aktiv bestanddel |
US09/720,675 US6462081B1 (en) | 1998-07-15 | 1999-07-14 | 5-thia-ω-substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient |
CA002336952A CA2336952C (en) | 1998-07-15 | 1999-07-14 | 5-thia-.omega.-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient |
AU46518/99A AU763668B2 (en) | 1998-07-15 | 1999-07-14 | 5-Thia-omega-substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient |
BRPI9912813-6A BR9912813B1 (pt) | 1998-07-15 | 1999-07-14 | derivados de fenil-prostaglandina e 5-tia-omega-substituìdos, processo para a produção dos mesmos, bem como composição e uso dos referidos derivados. |
HU0204170A HUP0204170A3 (en) | 1998-07-15 | 1999-07-14 | 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient |
DE69924258T DE69924258T2 (de) | 1998-07-15 | 1999-07-14 | Durch einen omega-thiarest substituierte phenyl-prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten |
NO20010213A NO327781B1 (no) | 1998-07-15 | 2001-01-12 | 5-tia-ω-substituerte fenyl-prostaglandin E-derivater |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20075298 | 1998-07-15 | ||
JP10/200752 | 1998-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000003980A1 true WO2000003980A1 (fr) | 2000-01-27 |
Family
ID=16429595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/003798 WO2000003980A1 (fr) | 1998-07-15 | 1999-07-14 | DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF |
Country Status (21)
Country | Link |
---|---|
US (1) | US6462081B1 (ja) |
EP (1) | EP1097922B1 (ja) |
JP (1) | JP3174563B2 (ja) |
KR (1) | KR100598660B1 (ja) |
CN (1) | CN1173945C (ja) |
AT (1) | ATE291013T1 (ja) |
AU (1) | AU763668B2 (ja) |
BR (1) | BR9912813B1 (ja) |
CA (1) | CA2336952C (ja) |
DE (1) | DE69924258T2 (ja) |
DK (1) | DK1097922T3 (ja) |
ES (1) | ES2239448T3 (ja) |
HU (1) | HUP0204170A3 (ja) |
NO (1) | NO327781B1 (ja) |
NZ (1) | NZ509293A (ja) |
PT (1) | PT1097922E (ja) |
RU (1) | RU2220135C2 (ja) |
TR (1) | TR200100623T2 (ja) |
TW (1) | TWI249520B (ja) |
WO (1) | WO2000003980A1 (ja) |
ZA (1) | ZA200100295B (ja) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001024800A1 (fr) * | 1999-10-07 | 2001-04-12 | Ono Pharmaceutical Co., Ltd. | Remedes contre le dysfonctionnement de l'erection |
WO2001037877A1 (fr) * | 1999-11-24 | 2001-05-31 | Ono Pharmaceutical Co., Ltd. | Medicaments pour des affections liees a la perte de masse osseuse |
EP1132086A2 (en) * | 2000-01-31 | 2001-09-12 | Pfizer Products Inc. | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
WO2002047669A1 (en) * | 2000-12-14 | 2002-06-20 | Glaxo Group Limited | Use of ep4 receptor agonists for treating neuropathic pain |
WO2003009872A1 (en) * | 2001-07-23 | 2003-02-06 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
WO2003016254A1 (fr) * | 2001-08-09 | 2003-02-27 | Ono Pharmaceutical Co., Ltd. | Composes derives d'acide carboxylique et medicaments comprenant ces composes comme principe actif |
WO2003041717A1 (fr) * | 2001-11-12 | 2003-05-22 | Ono Pharmaceutical Co., Ltd. | Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine |
WO2004032965A1 (ja) * | 2002-10-10 | 2004-04-22 | Ono Pharmaceutical Co., Ltd. | 内因性修復因子産生促進剤 |
JP2005537235A (ja) * | 2002-06-06 | 2005-12-08 | メルク フロスト カナダ アンド カンパニー | Ep4受容体作動薬、組成物及びその方法 |
JP2005537225A (ja) * | 2002-04-17 | 2005-12-08 | メディカル リサーチ カウンシル | 子宮の病態治療のためのFPレセプターアンタゴニスト又はPGF2αアンタゴニスト |
WO2006016695A1 (ja) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ep4アゴニストを含有してなる高カリウム血症の予防および/または治療剤 |
WO2006016689A1 (ja) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
WO2006075690A1 (ja) * | 2005-01-14 | 2006-07-20 | Ono Pharmaceutical Co., Ltd. | 安定な医薬組成物 |
WO2006118173A1 (ja) | 2005-04-28 | 2006-11-09 | Ono Pharmaceutical Co., Ltd. | 経皮吸収製剤 |
US7166631B2 (en) | 2001-02-09 | 2007-01-23 | Glaxo Group Limited | Benzo[f]isoindole derivatives with affinity to the EP4 receptor |
WO2007088190A1 (en) | 2006-02-03 | 2007-08-09 | Glaxo Group Limited | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists |
US7276531B2 (en) | 2003-03-03 | 2007-10-02 | Applied Research Systems Ars Holding N.V. | G-lactam derivatives as prostaglandin agonists |
WO2008050848A1 (fr) | 2006-10-26 | 2008-05-02 | Ono Pharmaceutical Co., Ltd. | Préparation adhésive |
WO2008071736A1 (en) | 2006-12-15 | 2008-06-19 | Glaxo Group Limited | Benzamide derivatives as ep4 receptor agonists |
JP2008533158A (ja) * | 2005-03-17 | 2008-08-21 | アラーガン、インコーポレイテッド | 炎症性腸疾患の処置 |
WO2008136519A1 (ja) | 2007-05-08 | 2008-11-13 | National University Corporation, Hamamatsu University School Of Medicine | Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤 |
US7465755B2 (en) | 2003-07-18 | 2008-12-16 | Laboratoires Serono Sa | Hydrazide derivatives as prostaglandin receptors modulators |
WO2009056582A1 (en) | 2007-11-02 | 2009-05-07 | Glaxo Group Limited | Novel compounds |
WO2010096123A2 (en) | 2008-10-29 | 2010-08-26 | Aerie Pharmaceuticals, Inc. | Amino acid salts of prostaglandins |
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
US20120136011A1 (en) * | 2010-07-30 | 2012-05-31 | Allergan, Inc. | Compounds and methods for skin repair |
US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
CN1893977B (zh) * | 2001-07-23 | 2012-12-05 | 小野药品工业株式会社 | 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物 |
WO2013167582A1 (en) | 2012-05-09 | 2013-11-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
WO2014069401A1 (ja) | 2012-10-29 | 2014-05-08 | 株式会社カルディオ | 肺疾患特異的治療剤 |
WO2014144781A1 (en) | 2013-03-15 | 2014-09-18 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
US10112920B2 (en) | 2008-07-25 | 2018-10-30 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US10174017B2 (en) | 2009-05-01 | 2019-01-08 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10472327B2 (en) | 2007-01-10 | 2019-11-12 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US10858339B2 (en) | 2017-03-31 | 2020-12-08 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US12018012B2 (en) | 2022-04-18 | 2024-06-25 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2303060A1 (en) * | 1999-04-14 | 2000-10-14 | United States Gear Corporation | Towed vehicle brake controller |
KR20020067594A (ko) * | 2000-01-05 | 2002-08-22 | 오노 야꾸힝 고교 가부시키가이샤 | 5-티아-ω-치환 페닐-프로스타글란딘 E-알콜, 이들의제조 방법 및 이들을 유효 성분으로서 함유하는 약제 |
US6586462B2 (en) * | 2000-10-20 | 2003-07-01 | Allergan, Inc. | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
CA2451393C (en) * | 2001-07-16 | 2011-01-04 | F. Hoffmann-La Roche Ag | 2 pyrrolidone derivatives as prostanoid agonists |
JP2003078830A (ja) * | 2001-09-03 | 2003-03-14 | Sony Corp | デジタル放送受信装置および通信情報伝送方法 |
WO2003030911A1 (en) * | 2001-10-08 | 2003-04-17 | Medical Research Council | Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus |
US20050059742A1 (en) * | 2001-10-31 | 2005-03-17 | Jabbour Henry Nicolas | Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia |
WO2003037373A1 (en) * | 2001-10-31 | 2003-05-08 | Medical Research Council | Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer |
MXPA04009036A (es) * | 2002-03-18 | 2005-01-25 | Pfizer Prod Inc | Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular. |
ATE401895T1 (de) * | 2002-08-09 | 2008-08-15 | Taisho Pharmaceutical Co Ltd | Antipruritisches mittel |
US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
JP4477504B2 (ja) * | 2002-11-13 | 2010-06-09 | 大正製薬株式会社 | 鎮痒剤 |
CN101328135A (zh) * | 2003-02-07 | 2008-12-24 | 小野药品工业株式会社 | 羧酸化合物 |
CA2563356A1 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
US20080132543A1 (en) * | 2004-10-26 | 2008-06-05 | Wha Bin Im | Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists |
GB0524103D0 (en) | 2005-11-26 | 2006-01-04 | Medical Res Council | Healing |
US7511168B2 (en) * | 2006-01-18 | 2009-03-31 | Shih-Yi Wei | Processes and intermediates for the preparations of prostaglandins |
US8637558B2 (en) | 2008-12-30 | 2014-01-28 | Industry-Academic Cooperation Foundation, Chosun University | Thiazolidinedione derivative and use thereof |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
BR112013021035A2 (pt) | 2011-02-17 | 2016-10-11 | Allergan Inc | composições e métodos de reposição de tecido macio aperfeiçoados |
EP2678022A2 (en) | 2011-02-23 | 2014-01-01 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814510A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123270A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123274A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814527A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2014015246A1 (en) | 2012-07-19 | 2014-01-23 | Cayman Chemical Company, Inc. | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
JP2016527006A (ja) | 2013-07-19 | 2016-09-08 | ケイマン ケミカル カンパニー, インコーポレーテッド | 骨成長を促進するための方法、システム、及び組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6379870A (ja) * | 1986-09-24 | 1988-04-09 | Teijin Ltd | プロスタグランジンe↓1誘導体の製造法 |
JPH03223244A (ja) * | 1989-02-20 | 1991-10-02 | Ono Pharmaceut Co Ltd | 5―ヘテロ―6―オキソ―pge誘導体、それらの製造方法およびそれらを含有する薬剤 |
JPH07233144A (ja) * | 1993-12-29 | 1995-09-05 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体、その塩およびその使用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58198466A (ja) | 1982-05-12 | 1983-11-18 | Teijin Ltd | 5−チアプロスタグランジン類およびその製造法 |
EP0386901A1 (en) | 1989-02-20 | 1990-09-12 | Ono Pharmaceutical Co., Ltd. | Novel 5-hetero-6-oxo-PGE derivatives |
-
1999
- 1999-07-09 TW TW088111637A patent/TWI249520B/zh not_active IP Right Cessation
- 1999-07-14 DK DK99929831T patent/DK1097922T3/da active
- 1999-07-14 DE DE69924258T patent/DE69924258T2/de not_active Expired - Lifetime
- 1999-07-14 NZ NZ509293A patent/NZ509293A/en not_active IP Right Cessation
- 1999-07-14 WO PCT/JP1999/003798 patent/WO2000003980A1/ja not_active Application Discontinuation
- 1999-07-14 TR TR2001/00623T patent/TR200100623T2/xx unknown
- 1999-07-14 CN CNB998097039A patent/CN1173945C/zh not_active Expired - Fee Related
- 1999-07-14 JP JP2000560089A patent/JP3174563B2/ja not_active Expired - Fee Related
- 1999-07-14 AT AT99929831T patent/ATE291013T1/de active
- 1999-07-14 BR BRPI9912813-6A patent/BR9912813B1/pt not_active IP Right Cessation
- 1999-07-14 EP EP99929831A patent/EP1097922B1/en not_active Expired - Lifetime
- 1999-07-14 AU AU46518/99A patent/AU763668B2/en not_active Ceased
- 1999-07-14 KR KR1020017000093A patent/KR100598660B1/ko not_active IP Right Cessation
- 1999-07-14 RU RU2001101470/04A patent/RU2220135C2/ru not_active IP Right Cessation
- 1999-07-14 CA CA002336952A patent/CA2336952C/en not_active Expired - Fee Related
- 1999-07-14 US US09/720,675 patent/US6462081B1/en not_active Expired - Fee Related
- 1999-07-14 HU HU0204170A patent/HUP0204170A3/hu unknown
- 1999-07-14 ES ES99929831T patent/ES2239448T3/es not_active Expired - Lifetime
- 1999-07-14 PT PT99929831T patent/PT1097922E/pt unknown
-
2001
- 2001-01-10 ZA ZA200100295A patent/ZA200100295B/en unknown
- 2001-01-12 NO NO20010213A patent/NO327781B1/no not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6379870A (ja) * | 1986-09-24 | 1988-04-09 | Teijin Ltd | プロスタグランジンe↓1誘導体の製造法 |
JPH03223244A (ja) * | 1989-02-20 | 1991-10-02 | Ono Pharmaceut Co Ltd | 5―ヘテロ―6―オキソ―pge誘導体、それらの製造方法およびそれらを含有する薬剤 |
JPH07233144A (ja) * | 1993-12-29 | 1995-09-05 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体、その塩およびその使用 |
Cited By (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
WO2001024800A1 (fr) * | 1999-10-07 | 2001-04-12 | Ono Pharmaceutical Co., Ltd. | Remedes contre le dysfonctionnement de l'erection |
US6710081B1 (en) | 1999-10-07 | 2004-03-23 | Ono Pharmaceutical Co., Ltd. | Erection insufficiency remedies |
WO2001037877A1 (fr) * | 1999-11-24 | 2001-05-31 | Ono Pharmaceutical Co., Ltd. | Medicaments pour des affections liees a la perte de masse osseuse |
EP1132086A2 (en) * | 2000-01-31 | 2001-09-12 | Pfizer Products Inc. | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
EP1132086B1 (en) * | 2000-01-31 | 2006-05-31 | Pfizer Products Inc. | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
US9675539B2 (en) | 2000-03-31 | 2017-06-13 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US9579270B2 (en) | 2000-03-31 | 2017-02-28 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
WO2002047669A1 (en) * | 2000-12-14 | 2002-06-20 | Glaxo Group Limited | Use of ep4 receptor agonists for treating neuropathic pain |
US7732622B2 (en) | 2001-02-09 | 2010-06-08 | Glaxo Group Limited | Naphthalene derivatives |
US7166631B2 (en) | 2001-02-09 | 2007-01-23 | Glaxo Group Limited | Benzo[f]isoindole derivatives with affinity to the EP4 receptor |
EP2255829A3 (en) * | 2001-07-23 | 2012-03-28 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient |
EP2255829A2 (en) | 2001-07-23 | 2010-12-01 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient |
CN1893977B (zh) * | 2001-07-23 | 2012-12-05 | 小野药品工业株式会社 | 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物 |
US8207223B2 (en) | 2001-07-23 | 2012-06-26 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient |
US7608637B2 (en) * | 2001-07-23 | 2009-10-27 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient |
KR100826866B1 (ko) * | 2001-07-23 | 2008-05-06 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제 |
WO2003009872A1 (en) * | 2001-07-23 | 2003-02-06 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
US7786161B2 (en) | 2001-08-09 | 2010-08-31 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient |
US7491748B2 (en) | 2001-08-09 | 2009-02-17 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
WO2003016254A1 (fr) * | 2001-08-09 | 2003-02-27 | Ono Pharmaceutical Co., Ltd. | Composes derives d'acide carboxylique et medicaments comprenant ces composes comme principe actif |
JPWO2003041717A1 (ja) * | 2001-11-12 | 2005-03-03 | 小野薬品工業株式会社 | プロスタグランジン誘導体を有効成分とする局所投与用持続性フィルム状製剤 |
WO2003041717A1 (fr) * | 2001-11-12 | 2003-05-22 | Ono Pharmaceutical Co., Ltd. | Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine |
JP2005537225A (ja) * | 2002-04-17 | 2005-12-08 | メディカル リサーチ カウンシル | 子宮の病態治療のためのFPレセプターアンタゴニスト又はPGF2αアンタゴニスト |
JP4766875B2 (ja) * | 2002-06-06 | 2011-09-07 | メルク フロスト カナダ リミテツド | Ep4受容体作動薬、組成物及びその方法 |
JP2005537235A (ja) * | 2002-06-06 | 2005-12-08 | メルク フロスト カナダ アンド カンパニー | Ep4受容体作動薬、組成物及びその方法 |
WO2004032965A1 (ja) * | 2002-10-10 | 2004-04-22 | Ono Pharmaceutical Co., Ltd. | 内因性修復因子産生促進剤 |
US7547715B2 (en) | 2002-10-10 | 2009-06-16 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production accelerator |
EP2465537A1 (en) | 2002-10-10 | 2012-06-20 | ONO Pharmaceutical Co., Ltd. | Microspheres comprising ONO-1301 |
US8436026B2 (en) | 2002-10-10 | 2013-05-07 | Ono Pharmaceutical Co., Ltd. | Endogeneous repair factor production promoters |
JP4497320B2 (ja) * | 2002-10-10 | 2010-07-07 | 小野薬品工業株式会社 | 内因性修復因子産生促進剤 |
US8642630B2 (en) | 2002-10-10 | 2014-02-04 | Ono Pharmaceutical Co., Ltd. | Endogeneous repair factor production accelerators |
JPWO2004032965A1 (ja) * | 2002-10-10 | 2006-02-09 | 小野薬品工業株式会社 | 内因性修復因子産生促進剤 |
US7276531B2 (en) | 2003-03-03 | 2007-10-02 | Applied Research Systems Ars Holding N.V. | G-lactam derivatives as prostaglandin agonists |
US7465755B2 (en) | 2003-07-18 | 2008-12-16 | Laboratoires Serono Sa | Hydrazide derivatives as prostaglandin receptors modulators |
WO2006016695A1 (ja) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ep4アゴニストを含有してなる高カリウム血症の予防および/または治療剤 |
US7858610B2 (en) | 2004-08-10 | 2010-12-28 | Ono Pharmaceutical Co., Ltd. | Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist |
JP4888775B2 (ja) * | 2004-08-10 | 2012-02-29 | 小野薬品工業株式会社 | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
WO2006016689A1 (ja) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
JPWO2006016689A1 (ja) * | 2004-08-10 | 2008-05-01 | 小野薬品工業株式会社 | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
WO2006075690A1 (ja) * | 2005-01-14 | 2006-07-20 | Ono Pharmaceutical Co., Ltd. | 安定な医薬組成物 |
JP2008533158A (ja) * | 2005-03-17 | 2008-08-21 | アラーガン、インコーポレイテッド | 炎症性腸疾患の処置 |
WO2006118173A1 (ja) | 2005-04-28 | 2006-11-09 | Ono Pharmaceutical Co., Ltd. | 経皮吸収製剤 |
EP2457897A1 (en) | 2006-02-03 | 2012-05-30 | Glaxo Group Limited | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists |
WO2007088190A1 (en) | 2006-02-03 | 2007-08-09 | Glaxo Group Limited | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists |
WO2008050848A1 (fr) | 2006-10-26 | 2008-05-02 | Ono Pharmaceutical Co., Ltd. | Préparation adhésive |
WO2008071736A1 (en) | 2006-12-15 | 2008-06-19 | Glaxo Group Limited | Benzamide derivatives as ep4 receptor agonists |
US10472327B2 (en) | 2007-01-10 | 2019-11-12 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US10899714B2 (en) | 2007-01-10 | 2021-01-26 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8507545B2 (en) | 2007-05-08 | 2013-08-13 | National University Corporation, Hamamatsu University School Of Medicine | Cytotoxic T cell activator comprising EP4 agonist |
WO2008136519A1 (ja) | 2007-05-08 | 2008-11-13 | National University Corporation, Hamamatsu University School Of Medicine | Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤 |
WO2009056582A1 (en) | 2007-11-02 | 2009-05-07 | Glaxo Group Limited | Novel compounds |
US10532993B2 (en) | 2008-07-25 | 2020-01-14 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US10112920B2 (en) | 2008-07-25 | 2018-10-30 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US10882840B2 (en) | 2008-07-25 | 2021-01-05 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US11021456B2 (en) | 2008-07-25 | 2021-06-01 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
WO2010096123A2 (en) | 2008-10-29 | 2010-08-26 | Aerie Pharmaceuticals, Inc. | Amino acid salts of prostaglandins |
US11618748B2 (en) | 2009-05-01 | 2023-04-04 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US11028081B2 (en) | 2009-05-01 | 2021-06-08 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10654844B2 (en) | 2009-05-01 | 2020-05-19 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10174017B2 (en) | 2009-05-01 | 2019-01-08 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10316029B2 (en) | 2009-05-01 | 2019-06-11 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US20120136011A1 (en) * | 2010-07-30 | 2012-05-31 | Allergan, Inc. | Compounds and methods for skin repair |
US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
WO2013167582A1 (en) | 2012-05-09 | 2013-11-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
WO2014069401A1 (ja) | 2012-10-29 | 2014-05-08 | 株式会社カルディオ | 肺疾患特異的治療剤 |
US10568878B2 (en) | 2013-03-15 | 2020-02-25 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9415043B2 (en) | 2013-03-15 | 2016-08-16 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9993470B2 (en) | 2013-03-15 | 2018-06-12 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US10588901B2 (en) | 2013-03-15 | 2020-03-17 | Aerie Pharmaceuticals, Inc. | Combination therapy |
EP4335507A2 (en) | 2013-03-15 | 2024-03-13 | Aerie Pharmaceuticals, Inc. | Combination therapy |
EP4218759A2 (en) | 2013-03-15 | 2023-08-02 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9931336B2 (en) | 2013-03-15 | 2018-04-03 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9849122B2 (en) | 2013-03-15 | 2017-12-26 | Aerie Pharmaceuticals, Inc. | Combination therapy |
EP3811943A1 (en) | 2013-03-15 | 2021-04-28 | Aerie Pharmaceuticals, Inc. | Compound for use in the treatment of ocular disorders |
US11020385B2 (en) | 2013-03-15 | 2021-06-01 | Aerie Pharmaceuticals, Inc. | Combination therapy |
WO2014144781A1 (en) | 2013-03-15 | 2014-09-18 | Aerie Pharmaceuticals, Inc. | Combination therapy |
EP3461484A1 (en) | 2013-03-15 | 2019-04-03 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US11185538B2 (en) | 2013-03-15 | 2021-11-30 | Aerie Pharmaceuticals, Inc. | Compositions for treating glaucoma or reducing intraocular pressure |
US11197853B2 (en) | 2013-03-15 | 2021-12-14 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11590123B2 (en) | 2016-08-31 | 2023-02-28 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11707460B2 (en) | 2016-08-31 | 2023-07-25 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11312700B2 (en) | 2017-03-31 | 2022-04-26 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US10858339B2 (en) | 2017-03-31 | 2020-12-08 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11891376B2 (en) | 2018-09-14 | 2024-02-06 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US12018012B2 (en) | 2022-04-18 | 2024-06-25 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Also Published As
Publication number | Publication date |
---|---|
NO327781B1 (no) | 2009-09-21 |
TR200100623T2 (tr) | 2001-06-21 |
KR100598660B1 (ko) | 2006-07-13 |
AU763668B2 (en) | 2003-07-31 |
US6462081B1 (en) | 2002-10-08 |
KR20010053386A (ko) | 2001-06-25 |
HUP0204170A2 (hu) | 2003-04-28 |
JP3174563B2 (ja) | 2001-06-11 |
BR9912813B1 (pt) | 2010-11-30 |
PT1097922E (pt) | 2005-06-30 |
BR9912813A (pt) | 2001-05-02 |
NZ509293A (en) | 2003-05-30 |
DE69924258D1 (de) | 2005-04-21 |
EP1097922A4 (en) | 2003-02-12 |
CA2336952C (en) | 2009-09-15 |
DK1097922T3 (da) | 2005-05-30 |
CN1173945C (zh) | 2004-11-03 |
CA2336952A1 (en) | 2000-01-27 |
NO20010213L (no) | 2001-03-15 |
NO20010213D0 (no) | 2001-01-12 |
DE69924258T2 (de) | 2006-01-26 |
EP1097922A1 (en) | 2001-05-09 |
TWI249520B (en) | 2006-02-21 |
ES2239448T3 (es) | 2005-09-16 |
RU2220135C2 (ru) | 2003-12-27 |
AU4651899A (en) | 2000-02-07 |
HUP0204170A3 (en) | 2005-03-29 |
CN1312796A (zh) | 2001-09-12 |
EP1097922B1 (en) | 2005-03-16 |
ATE291013T1 (de) | 2005-04-15 |
ZA200100295B (en) | 2002-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000003980A1 (fr) | DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF | |
WO2003013541A8 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
CA2368347A1 (en) | Glucokinase activators | |
CA2448602A1 (en) | Pyrimidine, triazine and pyrazine derivatives as glutamate receptors | |
CA2116785A1 (en) | Sustained Release Organic Nitrite Therapy | |
WO2004012700A3 (en) | Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release | |
HUE026166T2 (en) | New epoprosthenol preparation and procedure | |
JP2002537258A5 (ja) | ||
JP2001513506A5 (ja) | ||
CA2072233A1 (en) | Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them | |
EP1258473A4 (en) | BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL PRODUCT CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENT | |
WO2004022699A3 (en) | Liquid stable composition of oxazaphosphorine with mesna | |
ES2215327T3 (es) | Composicion de medicamento inmunomodulador. | |
Kerr et al. | Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analog 2', 3'-dideoxycytidine and its 3'-fluoro derivative | |
NO20010454L (no) | Anvendelse av derivater av camptotécin med en redusert gastrointestinal toksisitet | |
US4988678A (en) | Combinations of FU and BVU as anti-adenocarcinoma agents | |
ES2247060T3 (es) | Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial. | |
MD554G2 (ro) | Derivaţi noi ai triazolpirimidinelor, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice care le conţin | |
IL59507A (en) | 5-(10-9)abeo-6-methylergoline derivatives,their preparation and pharmaceutical compositions containing them | |
IL148739A0 (en) | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use | |
YU25202A (sh) | Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera | |
EP0345598A3 (de) | Zytostatisch wirksame Anthracyclinderivate | |
JP4426654B2 (ja) | 免疫調節用医薬組成物 | |
JP2006503049A5 (ja) | ||
JPS6213325B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99809703.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN HU JP KR MX NO NZ RU TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09720675 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017000093 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 46518/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2336952 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/00295 Country of ref document: ZA Ref document number: 509293 Country of ref document: NZ Ref document number: 200100295 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/000507 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999929831 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/00623 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999929831 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017000093 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 46518/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999929831 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017000093 Country of ref document: KR |